Outset Medical price target lowered to $7 from $17 at RBC Capital

RBC Capital analyst Shagun Singh lowered the firm’s price target on Outset Medical (OM) to $7 from $17 and keeps a Sector Perform rating on the shares as part of a broader research note previewing 2026 for Medical Supplies & Devices. The firm anticipates a year of positive momentum as sector fundamentals are solidly intact driven by the aging demographics, growing global healthcare access, and differentiated innovation, the analyst tells investors in a research note. For the company, RBC notes that Outset’s Q3 miss and resulting downward revision in guidance was driven by delays in executing the company’s commercial and sales transformation, as well as delays in closing several large deals that were originally anticipated in the second half of the year, and with execution misses in recent years, sentiment on the stock is “mixed at best”.